BioLife Solutions (BLFS) Stock Forecast, Price Target & Predictions
BLFS Stock Forecast
BioLife Solutions stock forecast is as follows: an average price target of $27.33 (represents a 9.28% upside from BLFS’s last price of $25.01) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
BLFS Price Target
The average price target for BioLife Solutions (BLFS) is $27.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $22.00. This represents a potential 9.28% upside from BLFS's last price of $25.01.
BLFS Analyst Ratings
According to 7 Wall Street analysts, BioLife Solutions's rating consensus is 'Buy'. The analyst rating breakdown for BLFS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioLife Solutions Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Jacob Johnson | Stephens | $30.00 | $21.57 | 39.05% | 19.95% |
| Aug 12, 2024 | Matt Hewitt | Craig-Hallum | $30.00 | $25.25 | 18.81% | 19.95% |
| Apr 04, 2024 | Matthew Stanton | Jefferies | $22.00 | $17.32 | 27.02% | -12.04% |
The latest BioLife Solutions stock forecast, released on Nov 15, 2024 by Jacob Johnson from Stephens, set a price target of $30.00, which represents a 39.05% increase from the stock price at the time of the forecast ($21.57), and a 19.95% increase from BLFS last price ($25.01).
BioLife Solutions Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $30.00 | $30.00 | $27.33 |
| Last Closing Price | $25.01 | $25.01 | $25.01 |
| Upside/Downside | 19.95% | 19.95% | 9.28% |
In the current month, the average price target of BioLife Solutions stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 19.95% increase as opposed to BioLife Solutions's last price of $25.01. This month's average price target is down 0.00% compared to last quarter, and up 9.77% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Stephens | Overweight | Overweight | Hold |
| Sep 30, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Aug 12, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jul 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 13, 2024 | Benchmark | - | Buy | Upgrade |
| Apr 04, 2024 | Jefferies | - | Buy | Initialise |
| Apr 25, 2022 | Oppenheimer | - | Outperform | Upgrade |
BioLife Solutions's last stock rating was published by Stephens on Nov 15, 2024. The company gave BLFS a "Overweight" rating, the same as its previous rate.
BioLife Solutions Financial Forecast
BioLife Solutions Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $32.73M | $33.33M | $39.51M | $37.70M | $44.26M | $40.75M | $40.53M | $36.22M | $37.30M | $33.80M | $31.20M | $16.85M | $14.73M | $11.28M | $9.92M | $12.16M | $8.30M | $6.60M |
| Avg Forecast | $36.95M | $35.56M | $35.06M | $32.68M | $28.46M | $27.94M | $25.72M | $23.81M | $22.95M | $25.54M | $23.95M | $26.01M | $33.40M | $33.01M | $43.63M | $42.94M | $43.40M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| High Forecast | $41.26M | $39.71M | $39.16M | $36.50M | $31.78M | $31.20M | $28.73M | $26.58M | $24.50M | $25.59M | $23.95M | $26.01M | $37.30M | $33.01M | $48.73M | $47.95M | $48.47M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| Low Forecast | $31.33M | $30.15M | $29.73M | $27.71M | $24.14M | $23.69M | $21.81M | $20.19M | $22.21M | $25.48M | $23.95M | $26.01M | $28.32M | $33.01M | $37.00M | $36.41M | $36.80M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.01% | 0.91% | 0.88% | 1.02% | 0.97% | 1.03% | 0.95% | 1.04% | 1.07% | 1.13% | 1.05% | 1.09% | 1.05% | 1.04% | 1.09% | 0.92% | 0.87% |
BioLife Solutions's average Quarter revenue forecast for Mar 24 based on 2 analysts is $26.01M, with a low forecast of $26.01M, and a high forecast of $26.01M. BLFS's average Quarter revenue forecast represents a -20.55% decrease compared to the company's last Quarter revenue of $32.73M (Dec 23).
BioLife Solutions EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-13.15M | $-11.36M | $-15.28M | $-11.03M | $-8.32M | $-3.10M | $-4.27M | $-9.77M | $-9.14M | $-13.54M | $2.42M | $1.86M | $-2.61M | $129.00K | $-122.00K | $1.66M | $454.00K | $38.00K |
| Avg Forecast | $-4.57M | $-4.40M | $-4.34M | $-4.04M | $-3.52M | $-3.46M | $-3.18M | $-2.94M | $-2.84M | $-3.16M | $-2.96M | $-4.50M | $-4.13M | $-4.08M | $-5.40M | $-4.81M | $-11.63M | $-6.09M | $-5.67M | $-4.37M | $-5.19M | $-4.58M | $-3.99M | $740.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| High Forecast | $-3.87M | $-3.73M | $-3.68M | $-3.43M | $-2.99M | $-2.93M | $-2.70M | $-2.50M | $-2.75M | $-3.15M | $-2.96M | $-3.60M | $-3.50M | $-4.08M | $-4.58M | $-3.85M | $-9.30M | $-6.09M | $-5.67M | $-3.50M | $-5.19M | $-4.58M | $-3.99M | $888.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| Low Forecast | $-5.10M | $-4.91M | $-4.84M | $-4.51M | $-3.93M | $-3.86M | $-3.55M | $-3.29M | $-3.03M | $-3.17M | $-2.96M | $-5.40M | $-4.61M | $-4.08M | $-6.03M | $-5.77M | $-13.96M | $-6.09M | $-5.67M | $-5.25M | $-5.19M | $-4.58M | $-3.99M | $592.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.18% | 2.78% | 2.83% | 2.29% | 0.72% | 0.51% | 0.75% | 2.23% | 1.76% | 2.96% | -0.61% | 2.52% | 1.33% | -0.08% | 0.09% | -1.03% | -0.35% | -0.03% |
2 analysts predict BLFS's average Quarter EBITDA for Sep 21 to be $-4.58M, with a high of $-4.58M and a low of $-4.58M. This is -288.70% lower than BioLife Solutions's previous annual EBITDA (Jun 21) of $2.42M.
BioLife Solutions Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-13.47M | $-29.13M | $-10.20M | $-13.71M | $-49.19M | $-9.96M | $-72.55M | $-7.07M | $-14.47M | $79.00K | $7.88M | $-1.12M | $-2.13M | $-1.13M | $-16.38M | $22.31M | $-12.24M | $9.32M |
| Avg Forecast | $1.85M | $923.51K | $923.51K | $461.75K | $-1.62M | $-1.27M | $-2.08M | $-3.12M | $-3.92M | $-3.62M | $-6.39M | $-9.59M | $-15.78M | $-17.32M | $-9.70M | $-10.26M | $-13.29M | $-7.59M | $-9.61M | $-9.33M | $-7.75M | $-3.94M | $-1.90M | $-1.40M | $-747.57K | $-722.91K | $-1.51M | $1.10B | $-817.86K | $1.07M |
| High Forecast | $2.13M | $1.06M | $1.06M | $531.80K | $-1.30M | $-1.02M | $-1.67M | $-2.50M | $-981.23K | $-2.90M | $-5.13M | $-7.67M | $-12.66M | $-13.89M | $-7.78M | $-8.21M | $-10.64M | $-7.59M | $-9.61M | $-7.46M | $-7.75M | $-3.94M | $-1.90M | $-1.12M | $-747.57K | $-722.91K | $-1.51M | $1.33B | $-817.86K | $1.07M |
| Low Forecast | $1.48M | $740.97K | $740.97K | $370.48K | $-1.86M | $-1.46M | $-2.39M | $-3.59M | $-8.83M | $-4.17M | $-7.36M | $-11.51M | $-18.17M | $-19.94M | $-11.17M | $-12.31M | $-15.95M | $-7.59M | $-9.61M | $-11.19M | $-7.75M | $-3.94M | $-1.90M | $-1.68M | $-747.57K | $-722.91K | $-1.51M | $883.40M | $-817.86K | $1.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 1.68% | 1.05% | 1.34% | 3.70% | 1.31% | 7.55% | 0.76% | 1.87% | -0.02% | -4.15% | 0.80% | 2.85% | 1.57% | 10.84% | 0.02% | 14.96% | 8.68% |
BioLife Solutions's average Quarter net income forecast for Dec 21 is $-7.75M, with a range of $-7.75M to $-7.75M. BLFS's average Quarter net income forecast represents a -9916.33% decrease compared to the company's last Quarter net income of $79.00K (Sep 21).
BioLife Solutions SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $17.51M | $19.77M | $21.72M | $21.31M | $18.56M | $16.86M | $16.77M | $16.09M | $15.17M | $14.15M | $10.29M | $6.85M | $6.57M | $5.09M | $4.64M | $4.71M | $3.98M | $3.52M |
| Avg Forecast | $17.31M | $16.66M | $16.43M | $15.31M | $13.34M | $13.09M | $12.05M | $11.15M | $10.75M | $11.97M | $11.22M | $21.84M | $15.65M | $15.47M | $20.45M | $23.36M | $13.93M | $19.71M | $18.35M | $21.23M | $16.78M | $14.80M | $12.92M | $8.56M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| High Forecast | $19.33M | $18.60M | $18.35M | $17.10M | $14.89M | $14.62M | $13.46M | $12.46M | $11.48M | $11.99M | $11.22M | $26.21M | $17.48M | $15.47M | $22.83M | $28.03M | $16.72M | $19.71M | $18.35M | $25.48M | $16.78M | $14.80M | $12.92M | $10.28M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| Low Forecast | $14.68M | $14.13M | $13.93M | $12.99M | $11.31M | $11.10M | $10.22M | $9.46M | $10.41M | $11.94M | $11.22M | $17.47M | $13.27M | $15.47M | $17.34M | $18.69M | $11.15M | $19.71M | $18.35M | $16.99M | $16.78M | $14.80M | $12.92M | $6.85M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 1.28% | 1.06% | 0.91% | 1.33% | 0.86% | 0.91% | 0.76% | 0.90% | 0.96% | 0.80% | 0.80% | 1.04% | 1.01% | 1.04% | 0.90% | 0.94% | 0.98% |
BioLife Solutions's average Quarter SG&A projection for Mar 24 is $21.84M, based on 2 Wall Street analysts, with a range of $17.47M to $26.21M. The forecast indicates a 24.75% rise compared to BLFS last annual SG&A of $17.51M (Dec 23).
BioLife Solutions EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.67 | $-0.00 | $-0.32 | $-1.15 | $-0.23 | $-1.71 | $-0.17 | $-0.35 | - | $0.20 | $-0.07 | $-0.06 | $-0.04 | $-1.35 | $2.10 | $-0.59 | $0.97 |
| Avg Forecast | $0.04 | $0.02 | $0.02 | $0.01 | $-0.04 | $-0.03 | $-0.04 | $-0.07 | $-0.09 | $-0.08 | $-0.14 | $-0.31 | $-0.34 | $-0.38 | $-0.21 | $-0.21 | $-0.16 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| High Forecast | $0.05 | $0.02 | $0.02 | $0.01 | $-0.03 | $-0.02 | $-0.04 | $-0.05 | $-0.02 | $-0.06 | $-0.11 | $-0.25 | $-0.27 | $-0.30 | $-0.17 | $-0.17 | $-0.13 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| Low Forecast | $0.03 | $0.02 | $0.02 | $0.01 | $-0.04 | $-0.03 | $-0.05 | $-0.08 | $-0.19 | $-0.09 | $-0.16 | $-0.35 | $-0.39 | $-0.43 | $-0.24 | $-0.25 | $-0.19 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 1.79% | 0.00% | 1.50% | 7.13% | 1.39% | 8.19% | 0.65% | 2.08% | -0.02% | -4.85% | 1.89% | 3.98% | 2.42% | 41.09% | -76.36% | 33.19% | 41.57% |
According to 2 Wall Street analysts, BioLife Solutions's projected average Quarter EPS for Dec 21 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -8972.11% decrease compared to BLFS previous annual EPS of - (Sep 21).
BioLife Solutions Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NSTG | NanoString | $0.11 | $21.50 | 19445.45% | Buy |
| COO | Cooper Companies | $99.08 | $298.00 | 200.77% | Buy |
| AKYA | Akoya Biosciences | $2.16 | $5.30 | 145.37% | Buy |
| ANGO | AngioDynamics | $6.74 | $15.00 | 122.55% | Buy |
| TFX | Teleflex | $187.43 | $304.36 | 62.39% | Buy |
| ATRC | AtriCure | $36.03 | $49.57 | 37.58% | Buy |
| HAE | Haemonetics | $84.92 | $108.25 | 27.47% | Buy |
| ALC | Alcon | $85.50 | $93.89 | 9.81% | Buy |
| BLFS | BioLife Solutions | $25.01 | $27.33 | 9.28% | Buy |
| ICUI | ICU Medical | $167.59 | $172.00 | 2.63% | Buy |
| WST | West Pharmaceutical Services | $311.66 | $297.67 | -4.49% | Buy |
| RMD | ResMed | $241.55 | $219.13 | -9.28% | Hold |
| KRMD | KORU Medical Systems | $3.65 | $3.25 | -10.96% | Buy |
| ATR | AptarGroup | $168.73 | $138.00 | -18.21% | Buy |